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Background: Lipohypertrophy does not appear to be an adverse ART reaction while lipoatrophy is clearly
associated with the use of stavudine (d4T) and zidovudine (AZT). In low and middle income countries d4T has only
recently been phased out and AZT is still widely being used. Several case definitions have been developed to
diagnose lipodystrophy, but none of them are generalizable to sub-Saharan Africa where black women have less
visceral adipose tissue and more subcutaneous adipose tissue than white women. We aimed to develop a simple,
objective measure to define lipoatrophy and lipohypertrophy by comparing patient report to anthropometric and
dual-energy X-ray absorptiometry (DXA) -derived variables.
Methods: DXA and anthropometric measures were obtained in a cross sectional sample of black HIV-infected South
African men (n = 116) and women (n = 434) on ART. Self-reported information on fat gain or fat loss was collected
using a standard questionnaire. Receiver operating characteristic (ROC) curves were used to describe the performance
of anthropometric and DXA-derived variables using patient reported lipoatrophy and lipohypertrophy as the reference
standard.
Results: Lipoatrophy and lipohypertrophy were more common in women (25% and 33% respectively) than in men
(10% and 13% respectively). There were insufficient numbers of men with DXA scans for meaningful analysis. The best
predictors of lipoatrophy in women were the anthropometric variables tricep (AUC = 0.725) and thigh skinfold (AUC
=0.720) thicknesses; and the DXA-derived variables percentage lower limb fat (AUC = 0.705) and percentage lower limb
fat/height (AUC = 0.713). The best predictors of lipohypertrophy in women were the anthropometric variable waist/hip
ratio (AUC = 0.645) and the DXA-derived variable percentage trunk fat/percentage limb fat (AUC = 0.647).
Conclusions: We were able to develop simple, anthropometric measures for defining lipoatrophy and
lipohypertrophy, using a sample of black HIV-infected South African women with DXA scans. This is of particular
relevance in resource limited settings, where health professionals need simple and inexpensive methods of diagnosing
patients with lipoatrophy and lipohypertrophy.
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Antiretroviral therapy (ART) has significantly reduced
the morbidity and mortality of people infected with HIV
[1], however, long-term use of ART has been associated
with a number of metabolic complications such as dys-
glycaemia, insulin resistance, dyslipidaemia and lipody-
strophy [2]. Lipodystrophy is characterized by either
subcutaneous fat loss (lipoatrophy), which is most no-
ticeable in the face, limbs, and buttocks, or fat accu-
mulation (lipohypertrophy) seen in the abdomen, breast
or posterior neck, or a combination of both [3,4].
Both subjective and objective methods have been
used to diagnose lipodystrophy, resulting in a number
of case definitions. The most widely used subjective
methods of diagnosis are patient perception and report
[5,6], physician examination and report [7], and physician
confirmation of patient report [8-11]. Objective measures
include imaging by dual-energy X-ray absorptiometry
(DXA) [6,12,13] and computed tomography (CT) scans
[12,14]. These imaging measures are expensive and not
widely available in resource limited settings. Anthropo-
metric and DXA-derived variables have also been deve-
loped, in an attempt to provide standard measures of
defining lipodystrophy [15-17]. Furthermore, criteria estab-
lished to define lipodystrophy did not include data from
any African country. These diagnostic criteria may not be
generalizable to sub-Saharan Africans, as there are im-
portant ethnic differences in fat distribution, especially
in black women who have less visceral adipose tissue
and more subcutaneous adipose tissue than white
women [18-20].
Lipohypertrophy does not appear to be an adverse ART
reaction as participants on different ART drug regimens
gained similar amounts of trunk fat over time [21]. Lipoa-
trophy, in contrast is clearly an adverse ART reaction. The
use of stavudine (d4T) and zidovudine (AZT) is associated
with subcutaneous fat loss and is partially reversed after
changing to abacavir or tenofovir [21,22]. Lipoatrophy
remains common in low and middle income countries
where d4T has only recently been phased out and AZT
is still widely used [23]. However, even if lipohyper-
trophy is not associated with ART, lipodystrophy, and
lipoatrophy in particular, is independently associated
with an increased risk of vascular disease [24,25].
Therefore recognising lipodystrophy is important to
identify patients at risk for vascular disease so that
screening can be targeted for other vascular risk factors,
while recognising lipoatrophy is important so that d4T or
AZT can be substituted.
The aim of our study was to develop a simple, objec-
tive measure to define lipoatrophy and lipohypertrophy
by comparing patient report to anthropometric and
DXA-derived variables in a sample of black South
Africans on ART.Results
Participant characteristics are presented in Table 1. The
study sample consisted of 550 participants on ART.
Based on patient report, 121 (22%) had lipoatrophy and
157 (29%) had lipohypertrophy. Both lipoatrophy and
lipohypertrophy were significantly more common in fe-
males than in males (p ≤ 0.001). Participants with lipoa-
trophy had spent a significantly longer period of time on
ART (25 vs. 17 months) and a longer time on d4T (15.5
vs. 13 months).
Anthropometric variables are shown separately for
women and men (Tables 2 and 3 respectively). In women,
all median skinfold measurements, with the exception
of sub-scapular skinfold thickness, were significantly
lower in participants with lipoatrophy compared with
those without lipoatrophy. Measurements for waist cir-
cumference, waist/hip ratio and supra-iliac skinfold
thickness were significantly higher in women with lipo-
hypertrophy compared with those without lipohypertro-
phy. There were no statistically significant differences in
anthropometric variables in males with and without
lipoatrophy (Table 3). Males with lipohypertrophy had a
significantly (P = 0.008) greater thigh circumference
than those without (13.5 mm vs. 8.1 mm).
DXA-derived measures are shown for women only
(Table 4), as there were insufficient numbers of men
with DXA scans for meaningful analysis. Women with
lipoatrophy as well as those with lipohypertrophy, had
significantly higher percentage trunk fat/lower limb fat
and percentage trunk fat/total limb fat and significantly
lower percentage lower limb fat/BMI. Women with
lipoatrophy had significantly less percentage limb fat while
women with lipohypertrophy had significantly more per-
centage trunk fat.
ROC curves for lipoatrophy and lipohypertrophy were
generated and reported in female participants for an-
thropometric and DXA-derived variables with the highest
AUC’s (Figure 1). For lipoatrophy, the two anthropometric
variables with the highest AUC were tricep skinfold thick-
ness (AUC= 0.725) and thigh skinfold thickness (AUC=
0.720) and for lipohypertrophy they were waist/hip ratio
(AUC= 0.645) and waist circumference (AUC= 0.589).
For lipoatrophy, the two DXA-derived variables with the
highest AUC were the percentage of lower limb fat stan-
dardised to height (AUC= 0.713) and percentage lower
limb fat (AUC= 0.705) and for lipohypertrophy they were
percentage trunk fat/percentage total limb fat (AUC=
0.647) and percentage trunk fat/ percentage lower limb fat
(AUC= 0.646). An illustration of anthropometric and
DXA-derived variables in females is shown in Figure 2.
Optimum cut-points for lipoatrophy and lipohypertro-
phy variables, based on likelihood ratios, were selected.
Table 5 shows the sensitivity, specificity, likelihood ratios
and predictive values for the two anthropometric and

















Age 34 [30–42] 35 [30–41] 0.256 34 [29–41] 35 [30–41] 0.198
Current CD4 count 397 [249–539] 315 [218–481] 0.023 389 [248–548] 314 [220–481] 0.015
Time on ART (months) 25 [14–32] 17 [10–27] 0.001 20 [12–31] 17 [11–28] 0.080
Time on Stavudine (months) 15.5 [10–26] 13 [8–19] 0.004 13 [8–21] 13 [9–20] 0.961
n [%] n [%] n [%] n [%]
Sex
Males 12 [10.34] 104 [89.66] 0.001 15 [12.93] 101 [87.07] <0.001
Females 109 [25.12] 325 [74.88] 142 [32.72] 292 [67.28]
Highest standard passed
No schooling 6 [18.8] 26 [81.3] 0.289 9 [28.13] 23 [71.88] 0.272
Primary school 14 [15.4] 77 [84.6] 20 [21.98] 71 [78.02]
Secondary school 96 [23.4] 315 [76.6] 121 [29.44] 290 [70.56]
Tertiary 5 [31.3] 11 [68.8] 7 [43.75] 9 [56.25]
ART Regimen
First-line 99 [22.30] 345 [77.70] 0.730 130 [29.28] 314 [70.72] 0.608
Second-line 22 [20.75] 84 [79.25] 27 [25.47] 79 [74.53]
*based on patient report, those with moderate or severe fat loss in 2 or more regions.
**Wilcoxon Rank-sum (Mann–Whitney) tests for continuous variables and chi-square tests for binary variables.
***based on patient report, those with moderate or severe fat gain in 2 or more regions.
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trophy and lipohypertrophy at the optimum cut-points.
Discussion
We showed that simple anthropometric measures were at
least as good as DXA-derived measures to diagnose lipoa-
trophy and lipohypertrophy in African women on ART.
The best predictors of lipoatrophy in women were the
anthropometric variables tricep and thigh skinfold
thicknesses; and the DXA-derived variables percentage
lower limb fat and percentage lower limb fat/height.
The best predictors of lipohypertrophy in women were
the anthropometric variable waist/hip ratio and the
DXA-derived variable percentage trunk fat/percentage
limb fat. Women with lipoatrophy had considerably
smaller limb circumferences, limb skinfold thicknesses
and lower percentages of limb fat than women without
lipoatrophy, despite similar BMIs. Lipoatrophy and lipo-
hypertrophy were both more common in women than
in the small sample of men.
Previous studies, conducted in high-income countries,
developed objective measures for lipodystrophy, thus
combining lipoatrophic and lipohypertrophic individ-
uals [15-17]. They proposed the use of fat mass ratio
(FMR), defined as the ratio between the percentage of
trunk fat mass and the percentage of lower-limb fat
mass. We however sought to investigate lipoatrophyand lipohypertrophy as separate entities. Identification
of lipoatrophy is important as it is an adverse antiretro-
viral drug reaction, which improves on switching anti-
retroviral drugs [21]. Although lipohypertrophy is
thought to be a consequence of treating HIV infection
rather than an adverse antiretroviral drug reaction [21],
like lipoatrophy, it is associated with an increased risk
of vascular disease [26] therefore it is worth identifying
so that appropriate screening and prevention interven-
tions can be implemented.
Despite the subjective nature of assessing lipoatrophy
and lipohypertrophy by using patient self-report, previous
studies have shown a strong correlation between patient
and physician reported lipodystrophy scores [27-29]. In
South Africa, as well as in many other African countries,
nurses, rather than physicians, prescribe antiretroviral
therapy and follow up patients. For these reasons we
used patient self-report [5,6] as the reference measure
to define lipoatrophy and lipohypertrophy.
Our study, like several others [11,21], showed a signifi-
cant association between lipoatrophy and time on ART,
and time on d4T in particular. As South Africa has only
recently phased out d4T, and AZT is still being used, it
is not unexpected that a quarter of the women and a
tenth of the men, had lipoatrophy. The prevalence of
lipoatrophy found in this study is not easy to compare
with other studies as studies from high-income countries

















Height (m) 1.6 [1.5-1.6] 1.6 [1.5-1.6] 0.603 1.6 [1.6-1.6] 1.6 [1.5-1.6] 0.112
Weight (kg) 65.4 [56.0-74.5] 68.1 [58.9-80.9] 0.019 69.5 [60.7-80.4] 67.1 [57.6-79.3] 0.127
BMI 26.2 [23.8-29.3] 27.1 [24.1-31.6] 0.036 27.4 [24.6-31.3] 26.65 [23.9-31.2] 0.187
Sagittal Abdominal Diameter (cm) 20.5 [19.0-23.0] 20.0 [18.5-23.0] 0.552 21 [19–24] 20 [18–23] 0.004
Circumferences
Waist (cm) 86.3 [79.5-96.3] 87.0 [78.5-97.0] 0.704 90.7 [80.3-98.5] 86 [78.4-95] 0.003
Hip (cm) 98.0 [92.0-104.0] 102.0 [95.0-112.0] <0.001 100 [95–110] 101 [94–110] 0.824
Waist/hip ratio 0.90 [0.83-0.94] 0.85 [0.80-0.90] <0.001 0.89 [0.83-0.93] 0.84 [0.79-0.90] <0.001
Mid-upper arm (cm) 27.0 [25.0-29.0] 29.0 [26.5-32.0] <0.001 28 [26–32] 28 [26–32] 0.789
Mid-thigh (cm) 54.5 [51.0-59.0] 57.0 [53.0-63.0] <0.001 56 [52–61] 57[ 52–63] 0.589
Skinfolds
Bicep (mm) 6.0 [4.4-8.4] 8.1 [5.7-11.7] <0.001 7.1 [5.2-10.7] 8 [5.4-11.45] 0.189
Tricep (mm) 13.3 [9.5-17.4] 18.4 [13.6-26.0] <0.001 16.2 [12–22] 18.3 [13–25.15] 0.059
Abdomen (mm) 20.4 [11.9-30.0] 24.4 [16.8-35.3] 0.001 24.1 [15.9-35.8] 23.6 [15.0-31.2] 0.210
Thigh (mm) 23.8 [15.4-32.8] 34.7 [24.2-44.7] <0.001 29.8 [20.5-42.5] 32.0 [22.5-43.5] 0.359
Sub-Scapular (mm) 16.9 [12.5-23.0] 19.2 [12.2-28.8] 0.058 20 [14.8-29.4] 18.5 [11.7-27.1] 0.050
Supra-iliac (mm) 13.2 [7.7-18.7] 15.1 [8.8-22.8] 0.033 16.6 [9.9-24.0] 13.9 [8.2-21.7] 0.022
Calf (mm) 10.8 [8.0-17.5] 17.5 [12.2-24.2] <0.001 15.6 [9.2-21.3] 17.3 [11.4-23.6] 0.061
*based on patient report, those with moderate or severe fat loss in 2 or more regions.
**Wilcoxon Rank-sum (Mann–Whitney) tests for continuous variables and chi-square tests for binary variables.
***based on patient report, those with moderate or severe fat gain in 2 or more regions.
Abrahams et al. AIDS Research and Therapy 2014, 11:26 Page 4 of 9
http://www.aidsrestherapy.com/content/11/1/26focussed on men [12,24], while most studies from Africa
looked at the prevalence of lipodystrophy [30-32] rather
than studying the two entities of lipoatrophy and lipody-
strophy separately. Our finding that tricep skinfold
thickness was a predictor of lipoatrophy is supported by
other studies. George et al. [33], using a small sample of
HIV-infected South Africans, found that after 2 years of
exposure to ART, patients had significantly decreased
tricep skinfold thicknesses. Similarly, a Ugandan study
using a sample of HIV-infected men and women [32],
found that decreased tricep skinfold thicknesses was as-
sociated with the use of AZT.
There were some limitations to our study. The cross
sectional design, while allowing us to make associations,
does not allow us to infer causality. With changes in fat
distribution, repeated objective measures would have
given us a better reference standard than patient report,
even though patient report is commonly used [5,6]. We
did not have enough men with lipoatrophy or lipohy-
pertrophy, to explore predictive anthropometric and
DXA-derived variables. Finally, the likelihood ratios for
the most predictive anthropometric and DXA-derived
variables were only weakly diagnostic of self-report
lipoatrophy and lipohypertrophy. Future research oflongitudinal studies in African cohorts, using changes in
DXA-derived variables as the reference standard, is
needed to confirm the value of anthropometric measures
for the diagnosis of lipoatrophy and lipohypertrophy.
Conclusion
Using a large sample of black HIV-infected South African
women who had DXA scans performed, we were able to
develop anthropometric measures for defining lipoatro-
phy and lipohypertrophy. The development of an-
thropometric measures which admittedly needs training
and well maintained skinfold callipers to ensure their
accuracy, are of particular relevance in resource limited
settings, where health professionals need simple and in-




A convenience sample of HIV-infected black men and
women presenting to ART clinics in Cape Town were se-
lected. The recruitment procedure is described else-
where [34]. The study sample comprised 116 male and
434 female participants on ART. At the time of the study

















Height (m) 1.7 [1.6-1.7] 1.7 [1.6-1.7] 0.942 1.7 [1.6-1.8] 1.7 [1.7-1.7] 0.954
Weight (kg) 65.5 [59.7-68.6] 63.5 [57.0-74.4] 0.895 67.4 [57.8-78.3] 62.7 [57.3-73.4] 0.408
BMI 23.3 [20.2-23.9] 22.4 [20.6-25.2] 0.772 23.6 [21.1-25.5] 22.3 [20.5-24.8] 0.324
Sagittal Abdominal Diameter (cm) 17.0 [16.0-19.5] 18.0 [17.0-20.0] 0.384 17.0 [16.0-22.0] 18.0 [17.0-20.0] 0.967
Circumferences
Waist (cm) 81.75 [77–84.9] 80.4 [75.0-90.2] 0.953 83.8 [75.0-97.0] 79.8 [75.8-89.5] 0.338
Hip (cm) 90 [87–93.5] 90.0 [85.0-97.0] 0.768 91.0 [85.0-97.0] 90.0 [85.0-96.0] 0.556
Waist/hip ratio 0.89 [0.85-0.95] 0.91 [0.87-0.94] 0.740 0.93 [0.86-0.97] 0.90 [0.86-0.94] 0.325
Mid-upper arm (cm) 27.0 [24–28.5] 26.0 [24.0-29.0] 0.877 27.0 [25.0-29.0] 26.0 [24.0-29.0] 0.817
Mid-thigh (cm) 50.5 [43.5-52.5] 49.0 [46.0-54.0] 0.401 49.0 [46.0-56.0] 49.0 [46.0-54.0] 0.567
Skinfolds
Bicep (mm) 3.9 [3.4-4.2] 3.5 [3.0-4.5] 0.329 4.1 [3.2-4.8] 3.5 [3.0-4.3] 0.180
Tricep (mm) 6.8 [5.6-8.2] 6.4 [5.1-9.3] 0.921 8.4 [5.0-11.4] 6.4 [5.1-8.7] 0.444
Abdomen (mm) 13.5 [10.5-16.9] 12.3 [8.5-30.1] 1.00 15.8 [9.3-28.2] 12.3 [8.5 -18.1] 0.309
Thigh (mm) 8.4 [7.2-14.8] 8.5 [6.0-12.4] 0.490 13.5 [8.4-21.1] 8.1 [6.0-11.3] 0.008
Sub-Scapular (mm) 9.4 [6.5-13.2] 8.3 [6.3-13.4] 0.605 10.5 [5.7-18.0] 8.2 [6.5-11.1] 0.770
Supra-iliac (mm) 6.3 [4.4-6.8] 6.2 [4.9-9.4] 0.196 6.4 [4.7-12.1] 6.2 [4.9-8.5] 0.934
Calf (mm) 5.5 [4.8-9.0] 5.8 [4.4-8.2] 0.739 6.8 [5.4-10.5] 5.5 [4.4-7.7] 0.094
*based on patient report, those with moderate or severe fat loss in 2 or more regions.
**Wilcoxon Rank-sum (Mann–Whitney) tests for continuous variables and chi-square tests for binary variables.
***based on patient report, those with moderate or severe fat gain in 2 or more regions.


















Arm fat (%) 37.4 [30.8-44.1] 38.3 [31.8-47.1] 0.380 39.8 [31.5-48.3] 38.1 [31.7-45.1] 0.319
Lower limb fat (%) 37.6 [31.5-40.6] 43.4 [36.6-49.7] 0.001 39.2 [33.3-49.7] 41.8 [36.3-48.8] 0.761
Trunk fat (%) 34.7 [29.9-38.0] 35.1 [27.9-43.1] 0.719 37.9 [30.7-45.3] 34.4 [26.6-40.4] 0.019
Lower limb fat/ht (%) 23.6 [19.7-25.4] 27.4 [23.4-31.5] 0.001 25.4 [21.9-31.1] 26.5 [23.2-29.7] 0.631
Total limb fat/ht (%) 22.7 [20.8-27.0] 25.4 [22.0-29.9] 0.015 25.4 [20.8-31.1] 25.2 [21.8-29.1] 0.825
Lower limb fat/BMI (%) 1.3 [1.2-1.7] 1.6 [1.3-1.8] 0.049 1.4 [1.2-1.6] 1.6 [1.3-1.8] 0.019
Total limb fat/BMI (%) 1.3 [1.3-1.6] 1.5 [1.3-1.6] 0.193 1.3 [1.2-1.5] 1.5 [1.3-1.7] 0.006
Trunk fat/lower limb fat (%) 0.94 [0.76-1.15] 0.83 [0.66-0.96] 0.017 0.93 [0.80-1.10] 0.81 [0.66-0.94] 0.003
Trunk fat/ total limb fat (%) 1.0 [0.8-1.0] 0.9 [0.7-1.0] 0.045 0.93 [0.85-1.03] 0.85 [0.72-0.97] 0.003
*based on patient report, those with moderate or severe fat loss in 2 or more regions.
**Wilcoxon Rank-sum (Mann–Whitney) tests for continuous variables and chi-square tests for binary variables.
***based on patient report, those with moderate or severe fat gain in 2 or more regions.
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Figure 1 ROC curves for the 2 anthropometric and DXA-derived variables with the highest AUC for lipoatrophy and lipohypertrophy in
female participants on ART.
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sing primary health care facilities. The first-line regimen
consisted of d4T, lamivudine (3TC) and efavirenz (EFV)
or nevirapine, and a second-line regimen consisting of
AZT with 3TC and lopinavir/ritonavir (LPV/r) [35].
Testing procedures
Questionnaires were used to collect socio-demographic
information from participants. Their clinical records atFigure 2 Lipoatrophy variables for female participants on ART with R
descending order of AUC.the health facilities were reviewed to obtain data on ART
regimen, time on ART, and CD4 count. Self-reported in-
formation on fat gain or fat loss was collected using a
standard questionnaire [8]. Lipoatrophy was defined as
moderate or severe fat loss in 2 or more regions and lipo-
hypertrophy defined as moderate or severe fat gain in two
or more areas [36].
Anthropometric measurements: [weight, height, cir-
cumferences (waist, hip, mid-upper arm, and mid-thigh),OC AUCs of ≥0.6 and their 95% confidence intervals in
Table 5 Variables for prediction and classification used to identify lipoatrophy and lipohypertrophy cut-points










Tricep skinfold ≤14.5 mm 418 0.62 0.71 2.13 0.53 0.42 0.85 68.66*
Thigh skinfold ≤28.0 mm 417 0.67 0.65 1.93 0.51 0.39 0.85 65.70*
% Lower limb fat/height≤ 24.7 418 0.19 0.85 1.28 0.95 0.30 0.76 68.42*
Lower limb fat (%)≤ 39.1 418 0.19 0.84 1.20 0.96 0.29 0.75 67.70*
Lipohypertrophy variable cut-point
Waist/Hip Ratio≥ 0.899 434 0.44 0.75 1.75 0.75 0.46 0.73 64.75**
Waist Circumference≥ 88.5 cm 434 0.57 0.59 1.40 0.73 0.41 0.73 58.53**
Trunk fat/total limb fat (%) ≥0.8895 172 0.50 0.70 1.66 0.72 0.38 0.79 64.5**
Trunk fat/leg fat (%)≥ 0.8816 172 0.72 0.61 1.84 0.46 0.40 0.86 64.0**
*percentage of those classified with and without lipoatrophy using the new cut-point compared to those defined by subject-report.
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suprailiac, thigh and calf ) and sagittal abdominal diam-
eter (SAD)] taken have previously been described [37].
DXA (Hologic Discovery-W, software version 12.7; scan
region 195 × 65 cm2 and weight limit 160 kg) was used
to measure fat mass and fat free soft tissue mass in a
subsample of participants (females: n = 172; males: n =
53). DXA cut off lines positioned at anatomical markers
were used to obtain fat mass for the whole body as well
as for the various regions of interest. A more detailed
description has been previously described [34].
Ethical approval
The study proposal was submitted and approved by the
Research Ethics Committee of the Faculty of Health
Sciences at the University of Cape Town. Written
informed consent was obtained from all participants
prior to participation in the study.
Data analyses
Data analysis was carried out using the STATA/SE statis-
tical software package version 12.0 (StataCorp., College
Station, TX, USA). Data were collected between February
2007 and June 2009. Participants were categorised into
those with and those without lipoatrophy. Continuous vari-
ables were described as medians and inter-quartile ranges
(IQR), and were compared using Wilcoxon Rank Sum tests.
Binary variables were described using chi-square tests.
Receiver operating characteristic (ROC) curves were
used to describe the performance of a number of an-
thropometric and DXA-derived variables using patient
reported lipoatrophy and lipohypertrophy as the refer-
ence standard. The area under the curve (AUC) was
used to assess the diagnostic performance of each vari-
able. In addition, sensitivity, specificity, likelihood ratios
and predictive values were calculated for variables with
the highest AUC at the optimum cut-points. Cut-point
selection was based on positive likelihood ratios.
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